News

This tripartite agreement leverages expertise in cell immunotherapies, peptide HLA (pHLA) binder discovery, and bispecific T cell engagers, with the aim of overcoming challenges to achieving durable cancer

Following expansion, the site will cover over 200,000ft² and feature new technologies in sustainably designed facilities. The initial phase of expansion comprises a 31,000ft² building that will accommodate

The deal advances Biogen’s immunology strategy, focussing on established immune mechanisms that may address inflammatory disorders with considerable unmet need. Biogen’s early-stage immunology pipeline is bolstered by the

The focus of this partnership is to create a new vaccine utilising a non-replicating highly attenuated vaccinia virus, designed to enhance safety and reduce the risk of emergence

This comes just two weeks after its US Food and Drug Administration (FDA) approval. The approval is based on results from FIBRONEER-IPF, a Phase III trial in IPF

In preclinical and Phase I studies in healthy participants, PORT-77 demonstrated a substantial reduction of plasma protoporphyrin IX (PPIX) through rapid ABCG2 inhibition. This outcome has the potential

Under this agreement, McKesson will act as an authorised distributor for the immunotherapy that has received approval from the US Food and Drug Administration (FDA) to treat adults

This partnership will utilise Tempus’ de-identified multimodal database to guide the design of clinical trials. Under the multi-year agreement, Whitehawk will utilise Tempus’ real-world dataset to focus on

The inhaler administers three active ingredients through a single device, known as single inhaler triple therapy (SITT), which has already received approval in nearly 50 countries. It combines